key: cord-272796-7br822q3 authors: Shang, Luxiang; Shao, Mengjiao; Guo, Qilong; Shi, Jia; Zhao, Yang; Xiaokereti, Jiasuoer; Tang, Baopeng title: Diabetes Mellitus is Associated with Severe Infection and Mortality in Patients with COVID-19: A Systematic Review and Meta-analysis date: 2020-08-07 journal: Arch Med Res DOI: 10.1016/j.arcmed.2020.07.005 sha: doc_id: 272796 cord_uid: 7br822q3 Abstract Background and Aim Currently, the number of patients with coronavirus disease 2019 (COVID-19) infection is increasing rapidly worldwide. In this study, we aimed to assess whether diabetes mellitus (DM) would increase the risk of severe infection and death in patients with COVID-19. Methods We systematically searched the PubMed, Web of Science, MedRxiv and COVID-19 academic research communication platform for studies reporting clinical severity and/or overall mortality data on DM in patients with COVID-19 published up to July 10, 2020. The primary outcome was to compare the severe infection rate and mortality rate in COVID-19 patients with and without DM, and to calculate the odds ratio (OR) and 95% confidence interval (CI). Results A total of 77 studies involving 32,015 patients with COVID-19 were included in our meta-analysis. COVID-19 patients with DM had higher severe infection and case-mortality rates compared with those without DM (21.4 vs. 10.5% and 28.3 vs. 13.1%, respectively, all p <0.01). COVID-19 patients with DM were at significantly elevated risk of severe infection (OR = 2.49, 95% CI: 2.10-2.95, p <0.001) and mortality (OR = 2.22, 95% CI: 1.80-2.47, p <0.001). Conclusion DM is associated with increased risk of severe infection and higher mortality in patients with COVID-19. Our study suggests that clinicians should pay more attention to the monitoring and treatment of COVID-19 patients with DM. were among critical patients (5). Therefore, it is very important to identify predictors of severe infection and mortality for effective treatment and therapeutic intervention. Diabetes mellitus (DM) is a common underlying disease in patients with COVID-19. A meta-analysis including 76,993 patients with confirmed cases showed that the prevalence of DM in patients with COVID-19 was 7.87% (95% confidence interval [CI]: 6.57% -9.28%) (6) . Emerging evidence suggests that COVID-19 patients with DM have an increased risk of complications and poor prognosis (7) . A recent study showed that COVID-19 patients with DM had higher levels of serum inflammation-related biomarkers and increased risk of severe pneumonia, excessive uncontrolled inflammatory responses, and hypercoagulability compared with non-diabetic patients (8) . In the present study, we performed a systematic review and meta-analysis to investigate the association of DM with disease severity and mortality in patients with COVID-19 and to provide reliable evidence for improved treatment and control of COVID-19. Our literature search was conducted in accordance with the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines (9) and was performed following the Preferred Reporting Items for Meta-Analyses (PRISMA) statement (10) . We searched PubMed, the Web of Science, MedRxiv (https://www.medrxiv.org) and COVID-19 academic research communication platform (http://medjournals.cn/2019NCP/index.do) on March 31, 2020 and up-dated the search on July 10, 2020. The search was limited to papers published in English or Chinese language. The following mesh-terms and free words were used: "COVID-19", "coronavirus disease 2019", "novel coronavirus pneumonia", "2019-nCoV", "SARS-CoV-2", "clinical characteristics", "clinical features", "outcome", "severe infection", "severe illness", "severity", "alive", "death", "mortality", "non-survivor", and "deceased", alone and in combination. The title, abstract, and full text of all documents identified with the search criteria were assessed. The reference lists of all studies were also analyzed to identify additional eligible studies. Only those research articles that reported data of DM and at least one outcome of interest were included in this meta-analysis. The primary outcomes were the pooled severe infection and mortality risk in COVID-19 patients with DM. Studies were excluded if they included duplicated results, reported insufficient data, or were case reports, case series with less than 20 patients, letters, review articles, editorial comments, guidelines or studies with animals. Studies that reported only deaths or critically ill cases were excluded. When single-center studies from the same hospital reported the same outcome with the study period overlapping by at least 50%, outcome from the study with the largest number of patients was extracted. Two investigators (MJS and LXS) independently scanned all the titles, abstracts and full text to identify studies that met the inclusion criteria and extracted data from these studies. Discrepancies between reviewers were resolved by discussion with a third reviewer (QLG) or by consensus. In this study, patients with severe infection were defined as those who met the diagnostic criteria of the Guidelines on the Diagnosis and Treatment of Novel Coronavirus Pneumonia (11) or were admitted to intensive care units. Data extraction and quality assessment of the included studies were also performed by two investigators (MJS and LXS) who performed the literature search. Data were collected and entered into a spreadsheet. We extracted the following variables: first author, study period, location, sample size, patient age range, sex, the number of participants with severe infection and/or death, and the prevalence of comorbidities. We used the Newcastle-Ottawa Scale (NOS) to assess the risk of bias of the included studies, and a NOS score >7 was considered good quality (12) . Statistical analysis was performed using the Meta package within R software (version 3. and its 95% CI were used to estimate the corelation between DM and severe infection and mortality in patients with COVID-19. We used a random-effects model to synthesize data for the relevant outcomes. Heterogeneity was evaluated using the χ 2 test and the I 2 statistic. For the χ 2 test, the significant heterogeneity among studies was indicated with a Cochran's Q p-value of <0.10. I 2 values of 25%, 25-50%, or 50% indicated low, moderate, or high heterogeneity, respectively (13) . If there was high heterogeneity, a sensitivity analysis was performed by removing each study from the meta-analysis (14) . Forest plots visually showed effect estimates of the included studies. We used funnel plots, Begg's test, and Egger's test to evaluate potential publication bias. A two tailed p <0.05 was considered statistically significant. The flow of studies through our meta-analysis is depicted in Figure 1 . A total of 77 studies with 32,015 patients were eventually included in our study . The characteristics of the included studies are described in Supplementary Table 1 A total of 29 studies reported an association between DM and mortality in patients with COVID-19. COVID-19 patients with DM had higher mortality rate compared with those non-diabetic patients The sensitivity analysis showed that none of the studies remarkably affected the pooled ORs and CIs Our results showed that diabetic patients with COVID-19 had higher severe infection and case-fatality rates compared with non-diabetic patients, and DM was associated with an increased risk of severe infection and mortality in patients with COVID-19. It remains unclear whether DM would increase the risk of SARS-CoV-2 infection, however, it has been observed that DM is a common underlying disease in patients with COVID-19. An early meta-analysis of 6 studies with 1,527 patients showed that hypertension (17.1%), cardio-cerebrovascular disease (16.4%), and DM (9.7%) were the most prevalent cardiovascular metabolic comorbidities in COVID-19 patients (7). An updated meta-analysis, including 83 studies and nearly 79,000 patients with laboratory-confirmed cases of COVID-19 showed that the prevalence of DM among COVID-19 patients was 14.34% (95% CI: 12.62-16.06 %) (92) . Therefore, patients with DM are suggested to pay attention to self-protection, and maintain good blood glucose control to reduce the risk of infection. However, so far, the mechanism leading to worse clinical outcomes in COVID-19 patients with DM has not been fully clarified. One possible reason is that DM is related to the activation of the renin-angiotensin system, and patients with DM are often treated with angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs), which may both lead to the This study has several limitations. First, while we excluded some studies manually to avoid including any duplicate studies, it is still possible that some overlapping patients were included in our meta-analysis, which might have some slight impact on our results. Second, the patients with COVID-19 in our meta-analysis had a high case-fatality rate, which may be due to these included studies during the early stages of the outbreak involving a higher proportion of severely ill patients. Therefore, the relationship between DM and mortality risk in mildly ill patients still needs to be evaluated. Third, different studies have different definitions of severe infection; at the same time, most studies were not adjusted for various confounding factors, such as data on diabetic medications, which might both cause bias in the results. Forth, the majority of the included studies in our meta-analysis were retrospective case-control studies, as the disease spreads around the world, it is hoped that other cohort studies and randomized studies will report more clinical data to verify our results, and further examine the effect of DM type, DM duration, presence of DM-related complications and glycaemic controls on prognosis of COVID-19. In conclusion, DM is related to a higher risk of severe infection and mortality. Therefore, it is needed to protect DM population from COVID-19 infection. Meanwhile, special care and monitoring are required in COVID-19 patients with DM to improve prognosis. All authors report no conflicts of interest related to this manuscript. WHO Declares COVID-19 a Pandemic Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19) World Health Organization. Coronavirus disease (COVID-2019) situation report -163 COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China Diabetes is a risk factor for the progression and prognosis of COVID-19 Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement National Health Commission of China. Diagnosis and treatment protocol for novel coronavirus pneumonia The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses Measuring inconsistency in meta-analyses Outlier and influence diagnostics for meta-analysis Clinical features of patients infected with 2019 novel coronavirus Clinical Characteristics of 138 Hospitalized Patients With Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical Characteristics of Coronavirus Disease 2019 in China Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19 Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study Clinical characteristics and outcomes of patients with severe covid-19 with diabetes Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan Risk Factors Associated with Clinical Outcomes Clinical Characterization of 162 COVID-19 patients in Israel: Preliminary Report from a Large Tertiary Center Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center Patients with diabetes are at higher risk for severe illness from COVID-19 Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019 Epidemiological and clinical features of 200 hospitalized patients with corona virus disease 2019 outside Wuhan, China: A descriptive study Clinical characteristics and risk factors for mortality among inpatients with COVID-19 in Wuhan, China Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: An experience from Oman Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran Clinical characteristics of Coronavirus Disease Clinical Characteristics of Patients Infected With the Novel The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab Clinical, radiological and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients hospitalised with COVID-19 in a Swiss area -a retrospective cohort study A cohort of patients with COVID-19 in a major teaching hospital in Europe A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19 A New Predictor of Disease Severity in Patients with COVID-19 Preprint at medRxiv Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan Characterization and clinical course of 1000 Patients with COVID-19 in New York: retrospective case series Clinical characteristics of 101 COVID-19 nonsurvivors in Wuhan, China: a retrospective study Clinical characteristics of Coronavirus Disease 2019 (COVID-19) patients in Kuwait Clinical Characteristics of Coronavirus Disease 2019 in Hainan, China. Preprint at medRxiv Clinical characteristics of imported and second-generation COVID-19 cases outside Wuhan, China: A multicenter retrospective study Clinical predictors of COVID-19 mortality. Preprint at medRxiv COVID-19: age, Interleukin-6, C-Reactive Protein and lymphocytes as key clues from a multicentre retrospective study in Spain Early Prediction of Disease Progression in 2019 Novel Coronavirus Pneumonia Patients Outside Wuhan with CT and Clinical Characteristics Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei Epidemiological and clinical features of 2019-nCoV acute in Chongqing municipality, China: a retrospective, descriptive, multiple-center study History of coronary heart disease increases the mortality rate of COVID-19 patients: a nested case-control study Influence factors of death risk among COVID-19 patients in Wuhan, China: a hospital-based case-cohort study Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study. Preprint at medRxiv Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study Myocardial characteristics as the prognosis for COVID-19 Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage Potential Factors for Prediction of Disease Severity of COVID-19 Patients. Preprint at medRxiv Prognostic Factors In Spanish Covid-19 Patients: A Case Series From Barcelona. Preprint at medRxiv Progression, recovery and fatality in patients with SARS-CoV-2 related pneumonia in Wuhan, China: a single-centered, retrospective, observational study The characteristics and death risk factors of 132 COVID-19 pneumonia patients with comorbidities: a retrospective single center analysis in Wuhan Clinical Characteristics of SARS-CoV-2 Infections Involving 325 Hospitalized Patients outside Wuhan Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy Prevalence and impact of diabetes among people infected with SARS-CoV-2 Commentary: COVID-19 and diabetes COVID-19 and diabetes COVID-19 and its implications for thrombosis and anticoagulation Covid-19 and diabetes mellitus: unveiling the interaction of two Management suggestions for patients with diabetes and novel coronavirus pneumonia COVID-19 in patients with diabetes: risk factors that increase morbidity Care for diabetes with COVID-19: Advice from China COVID-19 and endocrine diseases. A statement from the Our meta-analysis shows that diabetes is a predictor of severe infection and death in COVID-19 patients This suggests that doctors and nurses should strengthen the attention to COVID-19 patients with diabetes This study was supported by National Key R&D Program of China (Grant number: 2016YFC0900905). We thank AJE (American Journal Experts) and "HOME for Researchers" for